Executive summary
The objective of this project is the identifi cation of at least 50 carcinogens that are relevant for workers' exposure via inhalation at a considerable number of workplaces in Europe and thus, for which a Binding Occupational Exposure Limits (BOEL) under the Carcinogens and Mutagens Directive (CMD) might be suggested.
As a starting point, the terms 'carcinogen' and 'relevance' are defi ned for their use in the context of the project. In addition, the conditions under which an Occupational Exposure Limit Value (OEL) would be appropriate as a regulatory tool are refl ected on. Then the methods applied to select carcinogens and assess their relevance are detailed. In addition to carcinogens already included in Annex VI of the CLP regulation, further substances are considered to be future (or 'potential') carcinogens if they meet certain conditions, and are included in the analysis.
The main information sources utilised are the C&L Inventory, the REACH database on registered substances and compilations of substances included in various REACH processes, all available on the ECHA website, and the IARC classifi cation of carcinogens.
The analysis results in the selection of 187 carcinogens or groups of carcinogens divided into three categories of diff erent levels of relevance. For 71 of them a BOEL under the CMD might be suggested.
In an Annex, all selected carcinogens, complemented by additional information for further refi nement, are listed.
Introduction

Background to the project
In its resolution on the improvement of occupational health and safety in the European Union, adopted by the Executive Committee in December 2014, the European Trade Union Confederation (ETUC) called, among other issues, for the establishing of 50 binding limit values for carcinogenic substances in use at workplaces in the European Union. By this request, the ETUC is strongly supporting a proposal made by several EU Member States earlier in the year.
The proposal was made as part of a letter signed by the ministers of labour and social aff airs of Austria, Belgium, Germany and the Netherlands. It was sent to the then Commissioner in charge of the Directorate General on Employment, Social Aff airs and Inclusion in March 2014 in response to the decision of the Commission, announced in October 2013, to halt the revision of the Carcinogens and Mutagens Directive (Dir. 2004/37/EC -CMD for short) during its mandate as part of the so-called REFIT programme.
The need for an urgent update of the CMD was underlined in the ministers' letter by stressing that some 50,000 to 100,000 workers in the EU die each year as a result of exposure to carcinogenic substances and that more than 30 million workers are exposed to these substances beyond levels considered acceptable. In contrast, only three binding limit values have been established under the CMD at EU level, whereas some EU Member States have identifi ed limit values for carcinogens at national level. There are thus large diff erences in levels of protection in the EU. To ameliorate this situation, in their letter the four ministers point out that a future selection of only 50 substances could account for more than 80 or 90 per cent of all exposure situations to carcinogens. They therefore recommend that such a basic set of 50 high-quality Binding Occupational Exposure Limits (BOELs) should be established by 2020.
To identify relevant carcinogens that should be included in such a basic set of 50 substances, recent or still ongoing work at both Member State and EU level was utilised. In the Netherlands, since the mid-1990s risk-based Occupational Exposure Limit Values (OELs) have been derived for about 25 carcinogens. In Germany, since 2007 either risk-or health-based OELs have been derived or are still in the process of being derived for more than forty carcinogens. Last but not least, at EU level the derivation of BOELs for an additional 23 carcinogens was initiated in 2008. These substances could be used to constitute the core of the basic set addressed by the ministers.
Objectives and limitations
The objective of this project is the identifi cation of at least 50 carcinogens that can be considered to be relevant in the sense that a considerable number of workers in Europe are aff ected by exposure via inhalation to them.
To this end, two terms need to be defi ned in the context of this project, 'carcinogen' and 'relevance'. In addition, the exposure routes of the relevant carcinogens identifi ed have to be assessed, and carcinogens that are relevant with regard to dermal exposure only are to be excluded. Finally, it has to be considered whether -and if so, under what conditions -an OEL would be an appropriate regulatory instrument for mixtures of carcinogens.
Defi nition of 'carcinogen'
It has to be observed, however, that diff erent defi nitions of the term 'carcinogen' exist, depending on the respective context, be it regulatory or scientifi c. In the context of this project, precedence is given to the regulatory defi nition as established in Article 2 a) of the CMD. Based on that defi nition, all substances or mixtures included in Annex VI of the Classifi cation, Labelling and Packaging Regulation (Regulation (EC) No 1272/2008, CLP for short) classifi ed as C 1A, H350 or C 1B, H350 are considered to be carcinogens. In addition, all substances, mixtures or processes referred to in Annex I of the CMD, and all substances or mixtures released by a process referred to in Annex I of the CMD are also considered to be carcinogens.
Beside the regulatory defi nition, there are also scientifi c defi nitions of the term 'carcinogen'. Diff erent scientifi c bodies and committees, such as the International Agency for Research on Cancer (IARC), the Scientifi c Committee on Occupational Exposure Limits of the EU (SCOEL), or the German MAC Commission, have derived slightly diff ering defi nitions and categories for carcinogens. For this project, the IARC defi nitions and classifi cations are utilised as the relevant scientifi c defi nition. Details can be found at: http:// monographs.iarc.fr/ENG/Classifi cation/index.php.
'Relevance' of a carcinogen
From an occupational health and safety perspective, the relevance of a carcinogen is based on several factors:
-the number of workers exposed to it; -the extent of the exposure (level, duration and frequency of exposure); -the potency of the carcinogen, which can be indicated by its exposurerisk relationship
Given that quantitative data for these factors were available, both the statistical individual risk for any worker exposed to a specifi c carcinogen and the statistical collective risk of all workers exposed to that carcinogen could be calculated.
Assessments of the relevance of individual carcinogens could then be based on either the quantifi ed collective risk, or the frequency distribution of the quantifi ed individual risk, or a combination of both.
Because, however, the necessary data for the two former factors -that is, the number of workers exposed and the extent of their exposure -are not available, and information on the latter factor is limited (because exposure-risk relationships have been determined for a limited number of carcinogens as yet), the relevance of a carcinogen cannot be determined by this method. Instead, other criteria have to be employed.
Appropriateness of an OEL as a regulatory instrument
OELs are major tools for risk assessment of respiratory exposure. There, they serve two main functions:
(i) for the design of control measures, they defi ne the minimum level of protection; and (ii) for the assessment of the eff ectiveness of control measures applied, they are the yardsticks for the resulting exposure level and, thus, for the necessity of improving those control measures.
For dermal exposure, however, OELs might be of scientifi c and regulatory, but not of practical interest due to the absence of suitable instruments for monitoring dermal exposure at the workplace.
For mixtures of carcinogens, the appropriateness of an OEL, as a regulatory instrument, or of several OELs, as the case may be, depends on several aspects:
-Have the carcinogenic constituents of the mixture been identifi ed? In that case, for each of them the derivation of an OEL seems appropriate. -Alternatively, has the mixture as a whole been identifi ed as carcinogenic?
In that case, the derivation of an OEL seems appropriate only if there are measurement methods available for determining the concentration of either the mixture as a whole or a characteristic component of it in the workplace air. For the latter case, however, the composition of the mixture needs to be stable but not variable.
However, due to the variable composition of the constituents of certain complex carcinogenic mixtures, an OEL for the mixture as a whole does not seem to be an appropriate regulatory tool for such mixtures. Examples of such mixtures relevant at workplaces are listed in Table 1 . Report 136
Method -general defi nitions
The process of identifi cation and selection of 'relevant carcinogens', as discussed in the previous section, is done in two steps. First, both terms are specifi ed: which substances should be considered to be carcinogens in the context of this project, and what criteria should be employed to designate a carcinogen as a relevant one? Second, specifi c selection criteria for both categories are defi ned which enable the fi nal selection of 'relevant carcinogens' and their allocation to diff erent levels of relevance.
In this section, the fi rst step is addressed: the general schemes for identifying carcinogens and assessing substance relevance, respectively, are described, and the concrete combination of both items of information is presented.
Carcinogens
Given the purpose of this report -to provide a list of carcinogens for which BOELVs under the CMD should be established -substances selected should come within the scope of the CMD as defi ned in Art. 2 para. a) of the Directive (cf. sub-section 'Defi nition of 'carcinogen', above). For the purpose of simplifi cation, these carcinogens will be denoted 'actual regulatory carcinogens'. 
Process-generated Actual regulatory carcinogens placed on the market can be identifi ed via the publicly available database containing classifi cation and labelling information on notifi ed and registered substances (C&L Inventory) on the website of the European Chemicals Agency (ECHA) (http://echa.europa.eu/information-on-chemicals/cl-inventory-database). The additional process-generated regulatory carcinogens are referred to in Annex I of the CMD.
In addition to the 'actual regulatory carcinogens', in the context of this project additional substances are considered to be 'potential regulatory carcinogens'. A substance will be considered such a 'potential regulatory carcinogen' if one of the following four conditions is met:
(i) a process of harmonised classifi cation either as C 1A, H350 or as C 1B, H350 was initiated and resulted in an adoption by the Committee for Risk Assessment (RAC) of the ECHA by September 2015, but either subsequent legal procedures have not been fi nalised or the resulting adaptation to technical and scientifi c progress (ATP) has not come into force yet; information on such processes is available in the 'Opinions of the Committee for Risk Assessment on proposals for harmonised classifi cation and labelling' section of the ECHA website (http://echa.europa.eu/web/ guest/opinions-of-the-committee-for-risk-assessment-on-proposals-forharmonised-classifi cation-and-labelling); (ii) a process of harmonised classifi cation either as C 1A, H350 or as C 1B, H350 was initiated, but not fi nalised by November 2015; information on such processes is available in the 'Registry of Intentions' section of the ECHA website, both in the part 'Current CLH intentions' (http://echa. europa.eu/web/guest/registry-current-classifi cation-and-labelling-intentions) and in the part 'Submitted CLH proposals' (http://echa.europa. eu/web/guest/registry-of-submitted-harmonised-classifi cation-and-labelling-intentions); (iii) a substance is classifi ed by IARC (cf. Section 1.2, above) either as 'carcinogenic to humans' (group 1) or as 'probably carcinogenic to humans' (group 2A); information on the IARC classifi cation is available on the IARC website (http://monographs.iarc.fr/ENG/Classifi cation/vol1_112.php); or (iv) a substance without a harmonised classifi cation with regard to carcinogenicity has been notifi ed to ECHA by one or more manufacturers or importers either as C 1A, H350 or as C 1B, H350; information on such notifi cations is available in the C&L Inventory on the ECHA website (http:// echa.europa.eu/information-on-chemicals/cl-inventory-database).
Whereas conditions (i) to (iii) have been checked systematically for all entries in the respective list, no such systematic check has been undertaken for condition (iv). Not only is the number of substances with such notifi cations -with about 1,350 entries -rather large, but also the criteria for individual notifi cation applied by the respective notifi er (manufacturer or importer) are unknown to the public. Therefore, an outside observer is not in a position to assess whether such a notifi cation is justifi ed or not. Such ambiguities are underlined by the observation that, for a number of substances, only a single notifi er or a minority of notifi ers indicated a notifi cation either as C 1A, H350 or as C 1B, H350, whereas other notifi ers of the same substance indicated either no notifi cation for carcinogenicity or a notifi cation for suspected carcinogenicity (C 2, H351) only. In conclusion, substances with a notifi cation either as C 1A, H350 or as C 1B, H350 are included as 'potential regulatory carcinogens' only if other supporting evidence has been found, such as inclusion in the risk management option analysis (RMOA) (cf. the ECHA website: http:// echa.europa.eu/addressing-chemicals-of-concern/substances-of-potentialconcern/pact), inclusion in the Community Rolling Action Plan (CoRAP) (cf. the ECHA website: http://echa.europa.eu/information-on-chemicals/evaluation/community-rolling-action-plan/corap-table), or the derivation, or attempted derivation, of an exposure-risk relationship at national level.
It should also be noted that condition (iii) can also apply for process-generated carcinogens.
The reason for considering 'potential regulatory carcinogens' is the expectation that in the foreseeable future many of them will become 'actual regulatory carcinogens' by inclusion in Annex VI of the CLP regulation classifi ed as C 1A, H350 or C 1B, H350 or, in the case of process-generated carcinogens, by inclusion in Annex I of the CMD.
Relevance
In the absence of comprehensive knowledge on both the extent of exposure to the majority of carcinogens at workplaces in the EU and the potency of many carcinogens, surrogate signifi ers have to be employed to assess the relevance of individual carcinogens.
For substances placed on the market, an initial approach for approximating exposure information is the use of information on production or import volume. Such information is publicly available via a database containing information on substances registered under REACH on the ECHA website (http:// echa.europa.eu/information-on-chemicals/registered-substances) for carcinogens above a production or import volume above 1 tonne per year. For the purpose of this report, the following information is of particular signifi cance: registration status (full registration/ registration as intermediate/no registration), and tonnage band (in case of full registration).
Included in that database are substances notifi ed as new substances (NONS) under Dir. 67/548/EEC before REACH came into force. For them, less information is available than for substances registered under REACH. In particular, no information on production volume is publicly accessible.
For certain substances placed on the market, however, such registration information is not available. Active substances for use either in plant protection products or in biocidal products are regarded as being registered under REACH (cf. Art. 15 of the REACH regulation) and are therefore not necessarily contained in the abovementioned database. In the further analysis they are considered to be relevant if they are listed either in the Annex to Commission Implementing Regulation (EU) No. 540/2011 implementing Regulation (EC) No. 1107/2009 concerning the placing of plant protection products on the market, or are contained in the database on biocidal active substances on the ECHA website (http://echa.europa.eu/web/guest/information-on-chemicals/biocidal-active-substances).
Exempted from registration under REACH are substances used in medicinal products for human or veterinary use (cf. Art. 2 para 5 of the REACH regulation). Thus, also for them no registration information is available. Accordingly, in the further analysis such substances are considered to be relevant, given that their use in medicinal products could be identifi ed.
Process-generated substances are outside the scope of REACH as they are not placed on the market and, thus, for them no registration information exists.
As direct or indirect exposure information is not easily available for them either, in the further analysis process-generated carcinogens are generally considered to be relevant. Due to their comparatively small number and the issue of the appropriateness of an OEL as a regulatory instrument for those of them that are mixtures of diff erent substances (for details cf. Section 1.2, above), a case-by-case assessment could be performed for them at a later stage, if deemed necessary.
Relevant carcinogens
Because the number of actual regulatory carcinogens as defi ned above is rather large (the list of substances on the ECHA website with a harmonised classifi cation as C 1A, H350 or as C 1B, H350 -as updated on 30 October 2015 -comprised about 1,000 entries), that number is reduced in two ways, which are described in more detail in Section 1.4, below:
-carcinogenic metals and their compounds are combined to single entries ('metal' and their compounds); -petroleum and coal stream substances and mixtures are omitted As a result, the number of remaining actual regulatory carcinogens is reduced to about 200 entries. For potential regulatory carcinogens, due to their much smaller number, no such reduction was deemed necessary.
The relevance of each substance in the resulting sample of reduced actual regulatory carcinogens and all potential regulatory carcinogens is assessed by a tiered approach, consisting of the following fi ve steps:
As a fi rst step, for each substance it was checked whether it is process-generated, whether it should be considered to be a 'legacy substance' or whether it is presumably placed on the market. By the term 'legacy substance' in this report a substance is denoted which, although neither process-generated nor registered under REACH, can be present at a considerable number of work-places due to past uses. Legacy substances can be part of all sorts of objects and products, from industrial sites to buildings to machinery, vehicles and appliances. A number of tasks involving those objects and products -in particular maintenance and repair work, demolition or recycling -will result in exposure to legacy substances, such as asbestos, carcinogenic glass fi bres, PAHs or polychlorinated biphenyls (PCBs) for the foreseeable future.
As a second step, for each substance presumably placed on the market it was examined whether it has been registered under REACH and, if so, either with full registration, or with a registration for use as an intermediate only, or as a NONS substance.
As a third step, for carcinogens presumably placed on the market but without a registration under REACH, it was checked whether they are listed either as an active substance approved for use in plant protection products or as a biocidal active substance.
As a fourth step, for all remaining carcinogens presumably placed on the market -those without a registration under REACH, without a listing either as an active substance for plant protection or as a biocidal active substance -it was checked whether they are used in medicinal products.
As a fi fth and fi nal step, it was checked whether any of the remaining carcinogens presumably placed on the market (no registration under REACH, listed neither as an active substance for plant protection nor as a biocidal active substance, not used in medicinal products) are currently, or were in the past, subjected to certain regulatory processes at European level in the context of the REACH regulation, the CLP regulation or the CAD, or at national level in Germany or the Netherlands. Such processes are: -in the context of the REACH regulation and the CLP regulation, inclusion in the Candidate List of Substances of Very High Concern for Authorisation in accordance with Art. 59 (10) of the REACH Regulation (electronically accessible at: http://echa.europa.eu/candidate-list-table); or the intention, initiation or completion of a harmonised classifi cation as C 1A, H350 or as C 1B, H350; -in the context of the CAD, the development of a recommendation by SCOEL; -at national level, the derivation of an exposure-risk relationship (ERR), or an attempt to do so, in Germany or the Netherlands, or inclusion in the list of particularly hazardous carcinogens in the German Hazardous Substance Ordinance.
Method -specifi c selection criteria
In this section, the second step of the selection and diff erentiation process is addressed. By presenting detailed selection criteria, fi rst, the reduction of the number of actual regulatory carcinogens is explained, and second, the grading of relevance is outlined.
Selection of actual regulatory carcinogens
As indicated in the previous sub-section, two mechanisms were used to reduce the number of actual regulatory carcinogens by 80 per cent in preparation for the subsequent examination of their registration status under REACH. Both are explained in detail below.
Combination of carcinogenic metals and their compounds to single entries
For most metals for which an OEL has been derived, the scope of the OEL usually covers both the metal itself and its compounds or, as the case may be, its inorganic compounds. Therefore, it is assumed that if a BOEL were to be derived for a carcinogenic metal, that BOEL would cover all, or nearly all, of its compounds also classifi ed as carcinogens. Table 2 provides an overview of the six carcinogenic metals and their compounds classifi ed as carcinogens combined to a single entry each, covering 174 entries in total in the C&L Inventory on the ECHA website.
Petroleum and coal stream substances and mixtures
Most carcinogenic petroleum and coal stream substances and mixtures are complex mixtures; in addition, their composition can vary depending on the natural source from which the raw material originated. Therefore, deriving OELs for individual carcinogens from this class of substances would be futile, when specifi c measurands characterising the individual carcinogen cannot be determined. As a consequence, this whole group of substanceswhich comprises about 660 entries in the C&L Inventory on the ECHA website -are omitted from the further analysis unless they are subjected to one of the regulatory processes described in Section 1.3, sub-section 'Relevant carcinogens'.
This decision to omit nearly all carcinogens in that group should not be misconstrued to mean that all of them are to be considered to be 'not relevant' at workplaces. It implies only that deriving an OEL would not be an appropriate approach for regulating this group of substances. Instead, a diff erent approach seems to be warranted for dealing with them.
Some of the petroleum and coal stream substances and mixtures are classified as carcinogens due to their content of specific carcinogens, such as benzene, benzo(a)pyrene, or 1,3-butadiene, all of which are kept for the further analysis. In other words, OELs for the latter three carcinogens could be used for regulating the respective petroleum and coal stream substances.
The validity of this approach can be tested once fi rst results emerge from the working group to address petroleum and coal stream substances set up by ECHA in September 2015. As a fi rst step, a set of 65 of such substances with uses by consumers and in professional settings has been prioritised by the group. Once this list becomes publicly available, it can be checked whether for any of the substances the derivation of an OEL seems appropriate. In that case, the above argument on the futility of OELs for individual carcinogens from this class of substances would be invalidated as being too general.
Assessment of relevance of selected regulatory carcinogens
All carcinogens identifi ed as process-generated or as legacy substances are considered to be 'relevant', irrespective of any specifi c exposure information available, as for both categories the general assumption of widespread exposure in open processes can be made.
The relevance of carcinogens presumably placed on the market is graded either according to their registration status under REACH or to their identifi cation as a substance used in medicinal products or approved for use in plant protection products or biocidal products.
Relevance based on registration information
About 200 entries in the C&L Inventory on the ECHA website classifi ed as C 1A, H350 or as C 1B, H350 remained after the selection process described above. For each of them it was checked whether an entry existed in the database on registered substances on the ECHA website. Similarly, for each of the six combined entries for the carcinogenic metals it was checked whether an entry existed in the registration database for the metal itself or for at least one related compound.
In the same way, for all potential regulatory carcinogens (identifi ed by searching the lists on the ECHA website addressed in Section 1.3, subsection 'Carcinogens', above) their registration status under REACH was checked.
According to the type of registration, four diff erent levels of relevance are defi ned for the purpose of this project: -'relevance' for registration type 'full'; -'limited relevance' for registration type 'intermediate'; -'unclear relevance' for carcinogens either registered as 'NONS' or without registration which are, or have been, subjected to certain regulatory processes (as described in Section 1.3, sub-section 'Relevant carcinogens'); -'no relevance' for carcinogens without registration unless they meet the criterion described under 'unclear relevance', above.
This grading of the level of relevance of a carcinogen registered under REACH is based on the underlying defi nitions and obligations stipulated in the REACH regulation for substances placed on the market. A precondition for placing carcinogens on the market with a tonnage greater than 1 tonne per year is a registration according to Art. 6 of REACH. If the full spectrum of uses is to be covered, a complete registration is necessary in accordance with Art. 10 of REACH; if the carcinogen is to be manufactured and used as an on-site isolated intermediate under strictly controlled conditions only, in accordance with Art. 17 of REACH a less detailed registration suffi ces. For carcinogens manufactured and placed on the market below 1 tonne per year, registration is not requested.
As the term 'strictly controlled conditions' is specifi ed as meaning that the substance 'is rigorously contained by technical means during the whole lifecycle', workers should not be exposed to such substances during manufacture and use. Exposure might be possible, however, during control tasks and through repair and maintenance work. Due to these remaining possibilities for workers' exposure, carcinogens with a registration as on-site isolated intermediates are still considered as of limited relevance.
Due to the rather limited information publicly available for carcinogens listed as NONS, their relevance status cannot be decided because, depending on their actual use, they could have qualifi ed either for a full registration or for a registration as on-site isolated intermediates had they been registered according to the REACH criteria for phase-in substances. Thus, they are considered to be of unclear relevance.
In contrast, carcinogens placed on the market without any registration are generally considered to be of no relevance, although it is impossible to diff erentiate whether they are manufactured and placed on the market not at all or below a tonnage of 1 tonne per year.
A subset of carcinogens without any registration, which are, or have been, subjected to one of the regulatory processes described in Section 1.3, subsection 'Relevant carcinogens', is considered to be of unclear relevance because the mere existence of such processes is indicative of a certain level of relevance. However, without additional information on the reasons for the respective process, that level cannot be specifi ed for the particular carcinogen.
Additionally, two other groups are also considered to be of unclear relevance. Members of these groups have a full registration and are either: -notifi ed carcinogens belonging to the chemical group of fl uorinated hydrocarbons, but not subject to one of the regulatory processes described in Section 1.3, as their carcinogenicity might be closely related to the effects posed by two carcinogens classifi ed by IARC in group 2A (tetrafl uoroethylene and vinyl fl uoride); or -substances that are not regulatory carcinogens (according to the defi nitions given above), but whose carcinogenicity status is currently under discussion and, thus, which are subjected to ongoing regulatory processes.
Relevance based on use category
Carcinogens without any entry in the database on registered substances on the ECHA website, but listed either as an active substance approved for use in plant protection products or as a biocidal active substance are considered to be of limited relevance in the context of this report. This is due to two considerations: (i) in both regulations (on plant protection products and on biocidal products) the approval of carcinogens as active substances is supposed to be prohibited or restricted to stringent conditions; (ii) in both regulations, an Acceptable Operator Exposure Level (AOEL) might be established as part of the approval process for an active substance; thus, the derivation of a BOEL under the CMD would result in legal interference and should not be considered to be a viable option, accordingly.
In contrast, carcinogens without any entry in the database on registered substances on the ECHA website but used in medicinal products are considered to be of unclear relevance. This is due to the following considerations: -unavailability of any information on their actual use; -unavailability of any information on use conditions; -unavailability of any exposure information.
In addition, for this use category it remains to be discussed whether an OEL would be an appropriate regulatory tool or whether sector-specifi c control measures, analogous to those for laboratories, would be a better approach.
Refi nement of level of relevance of carcinogens placed on the market
The information publicly available for substances with a full registration would allow a further diff erentiation of the qualifi er 'relevance'. This could be based in particular on two parameters: the tonnage band for the production volume; and the identifi ed uses, expressed as process categories primarily for manufacture, formulation, uses at industrial sites, and uses by professional workers. Both pieces of information are accessible in the registration database on the ECHA website (http://echa.europa.eu/information-on-chemicals/registered-substances).
Due to the comparatively small number of substances identifi ed as 'relevant carcinogens' (cf. Section 2.1), a further diff erentiation based on the tonnage band is considered to be of low added value and, thus, not done for the time being. Instead, for each carcinogen with a full registration, the information on the tonnage band is listed in Tables 1-3 of the Annex.
In contrast, the information on process categories (PROCs) has been utilised as it facilitates deeper insight into potential exposure situations of workers. The following two process categories are considered to result in no exposure of workers, corresponding to the exposure situation of tasks involving intermediates: (i) PROC 1: use in closed process, no likelihood of exposure; (ii) PROC 3: use in closed batch process (synthesis or formulation).
For substances, for which solely PROC 1 or PROC 3 (or both) have been registered, the level of relevance is reduced to 'limited relevance'. The same is done for substances, for which, in addition to PROC 1 or PROC 3, one or more of the following three PROCs have been registered: (i) PROC 15: use as a laboratory agent; (ii) PROC 0: other: monomer in imported polymer; (iii) PROC 0: other: production of pharmaceuticals/vaccines. Report 136
Results
Carcinogens selected with diff erent levels of relevance
Altogether 187 carcinogens or groups of carcinogens have been selected and allocated to three diff erent relevance categories. These substances are listed in Tables 1-3 of the Annex.
Carcinogens considered to be relevant
This category for the highest level of relevance has been subdivided into two groups: (i) carcinogens for which an OEL is deemed appropriate, and (ii) carcinogens for which this is not the case.
Carcinogens for which an OEL would be appropriate
Based on the selection criteria described in Section 1.4, above, 47 actual regulatory carcinogens are selected as relevant, which are listed in Table  1 (Annex), including six substances that are not registered under REACH, but are process-generated or legacy carcinogens.
Based on the selection criteria described in Section 1.4, above, 24 potential regulatory carcinogens are selected as relevant that are also listed in Table 1 (Annex), including seven substances that are not registered under REACH, but are process-generated or legacy carcinogens. Two of the process-generated potential regulatory carcinogens have been recommended for inclusion in Annex I of the CMD.
Carcinogens for which an OEL might not be appropriate
Thirteen regulatory carcinogens (seven actual and six potential) from the group of PAHs and their nitro compounds have been included in a separate section in Table 1 (Annex). For them the derivation of an OEL is not deemed appropriate as they usually are part of mixtures of PAHs of variable composition (cf. Section 1.2, sub-section 'Appropriateness of an OEL as a regulatory instrument', above). An exemption is made for benzo(a)pyrene which is listed in the main section of Table 1 (Annex), because it serves two functions simultaneously: as a carcinogen in its own right and as a proxy for all other carcinogenic PAHs.
In addition, four regulatory carcinogens (two actual and two potential) from the group of petroleum and coal stream substances and mixtures have been included in another separate section in Table 1 (Annex). For them the derivation of an OEL is not deemed appropriate, as explained in Section 1.4, above.
Carcinogens considered to be potentially relevant
Based on the selection criteria described in Section 1.4, above, 35 carcinogens are considered to be potentially relevant which are listed in Table 2 (Annex); 28 of them are actual regulatory carcinogens, seven are potential.
Twenty-six of them are registered as intermediates only; four have full registration but the process categories (PROCs) registered for them indicate exposure levels of workers that correspond to those of tasks involving intermediates; the remaining fi ve have no registration, but are included either in the database on biocidal active substances or in the list of active substances authorised for use in plant protection products.
Carcinogens with unclear relevance
Based on the selection criteria described in Section 1.4, above, 64 carcinogens are considered to be of 'unclear relevance' which are listed in Table 3 (Annex): -18 of them are actual regulatory carcinogens without a registration under REACH subject to one of the regulatory processes described in Section 1.3, sub-section 'Relevant carcinogens'; -13 of them are actual regulatory carcinogens registered as NONS; -28 of them are potential regulatory carcinogens without a registration under REACH; 27 of these are used in medicinal products and, thus, are exempted from the registration obligation under REACH, the majority of them being drugs used in cancer treatment; the remaining one is subject to one of the regulatory processes described in Section 1.3, sub-section 'Relevant carcinogens'; -3 of them are potential regulatory carcinogens due to notifi cations with a full registration but without 'supporting evidence', as described in Section 1.3, sub-section 'Carcinogens'; instead, their identifi cation is justifi ed by their belonging to the same chemical class of fl uorinated hydrocarbons as Tetrafl uoroethylene and Vinyl fl uoride, both of which are classifi ed by IARC as 'probably carcinogenic to humans' (group 2A) and are, thus, selected as relevant carcinogens and listed in Table 1 (Annex), accordingly; and -2 of them are not classifi ed as carcinogens, but have a full registration under REACH and are subjected to one of the regulatory processes described in Section 1.3, sub-section 'Relevant carcinogens'.
Additional information in Tables 1-3 of the Annex
Additional information is provided in Tables 1-3 (Annex) in two diff erent ways, by subdividing each table into separate sections for specifi c classes of carcinogens, and by entering notes in diff erent columns on individual substances. This information might be useful for further refi nement of the level of relevance and for future decisions on the necessity of deriving a BOEL for the respective carcinogen.
Special classes of carcinogens
In chapter 1, a number of special classes of substances are addressed. To enable easier identifi cation of carcinogens belonging to one of these classes, in Tables 1-3 (Annex) they are displayed as separate sub-sections: -fl uorinated hydrocarbons; -polycyclic aromatic hydrocarbons (PAHs) and their nitro compounds; -petroleum and coal stream substances and mixtures; -substances notifi ed as new substances (NONS) under Dir. 67/548/EEC; -biocidal active substances or active substances authorised for use in plant protection products (PPP); -substances used in medicinal products. Standard information in column 3 is the harmonised classifi cation with regard to carcinogenicity as available from Annex VI of the CLP regulation. For carcinogens for which the intention of a process of harmonised classification is announced in a substance evaluation report or was formally notifi ed, or for which such a process was initiated, the intended or proposed harmonised classifi cation is specifi ed. For carcinogens without such information, the notifi ed self-classifi cation of the manufacturer or importer is specifi ed. For substances without a harmonised classifi cation as a carcinogen (C 1A/1B) which are classifi ed by IARC as group 1 or group 2A carcinogens, also the IARC classifi cation together with its year of publication is specifi ed.
Notes on classification, registration and regulatory processes
Standard information in column 4 for carcinogens with a full registration is the tonnage band; for other carcinogens it is specifi ed whether they are registered as intermediates only, as NONS, or not at all. Carcinogens with both a full registration and one for use as intermediates are denoted by the additional note a). Carcinogens approved as active substances in plant protection products are denoted by the entry 'PPP'; and carcinogens approved as biocidal active substances by the entry 'biocidal active substance'. Carcinogens that are process-generated or legacy substances are denoted by the entry 'process-generated' or 'legacy substance', respectively. For carcinogens used in medicinal products their use as an anti-cancer drug is denoted by the additional note b). For carcinogens with a full registration for which their level of relevance is changed from 'relevant' to 'potentially relevant' due to their process categories (PROCs) registered (cf. Section 1.4, sub-section 'Refi nement of level of relevance of carcinogens placed on the market'), the registered PROCs are also specifi ed.
For column 5 a variety of notes are foreseen, which are detailed in the Annex below Table 3 in sub-section 'Explanation of notes in Tables 1-3'. These notes are ordered in four groups, referring to REACH and CLP processes; OSH processes and instruments at EU level; OSH processes and instruments at Member State level (Germany); and OSH processes and instruments at Member State level (Netherlands).
For carcinogens registered as NONS, the type of substance is listed if specifi ed in the database. For six of them, 'polymer' is specifi ed.
In particular, the notes in column 5 are intended to facilitate access to additional publicly available information. For example, for the majority of REACH and CLP processes, substance-specifi c information, including information on use, is available on the ECHA website for the respective process.
Discussion
Combining classifi catory information from the CLP regulation and from IARC, on one hand, with registration information under REACH, information for plant protection products, for biocidal products, for medicinal products, and information from Annex I of the CMD on the other, 187 carcinogens or groups of carcinogens have been identifi ed as relevant and allocated to three categories of diff erent levels of relevance. A total of 115 of them are actual regulatory carcinogens, 72 are potential ones. The category for the highest level of relevance comprises 88 carcinogens (cf. Annex, Table 1), for 71 of which a BOEL under the CMD might be suggested.
Of the remaining 116 carcinogens, 13 are PAHs and 9 are petroleum and coal stream substances and mixtures, for which regulatory tools other than OELs seem more appropriate. Four carcinogens are active substances authorised for use in biocidal or plant protection products. The specifi c legislation applicable to them should take precedence to OSH legislation, so that for regulatory reasons the derivation of a BOEL under the CMD does not seem to be a priority issue. Another 26 carcinogens are either registered as intermediates only or their process categories (PROCs) registered indicate their exclusive use in a closed system. Also for them the derivation of an OEL does not seem to be a priority issue.
Whether the derivation of a BOEL under the CMD for any of the carcinogens from the group of 13 NONS will become a priority issue will depend on the future availability of additional information, in particular on production or import volume, and on use patterns.
For a group of fi ve potential regulatory carcinogens (including three fl uorinated hydrocarbons; listed in Annex, Table 3 ) with high or very high production volume (between 1,000 and 10,000,000 t/a each) there is currently no indication of an imminent CLH process that might result in their promotion to become an actual regulatory carcinogen. For this reason, the derivation of a BOEL under the CMD is not suggested for them. Due to their high volume, however, the derivation of an OEL under the CAD might be considered instead.
For the remaining 46 carcinogens, 28 of which are used in medicinal products, the currently available information, in particular on volume, use patterns and extent of exposure, is assessed as insuffi cient for suggesting the derivation of a BOEL under the CMD. Should, however, additional informa-tion become available, or the application of diff erent assessment criteria to the actual information be recommended, the derivation of a BOEL for additional carcinogens from this group might also be suggested.
For 57 of the 71 carcinogens or groups of carcinogens for which the derivation of a BOEL is suggested, tonnage information is available from their registration that might be used for prioritising the derivation of a BOEL. The annual volume produced or imported ranges from the lowest band (0-10 t) to the highest one (1,000,000-10,000,000 t) with a fairly smooth distribution across the whole range of seven bands.
For 29 of the 71 carcinogens or groups of carcinogens for which the derivation of a BOEL is suggested, neither a BOEL under the CMD is in existence or has been recommended by the Advisory Committee on Safety and Health (ACSH) as part of the revision of the CMD, nor is an IOELV under the CAD in existence or under preparation, nor have risk-based or health-based OELs in Germany or the Netherlands been derived or are under preparation. For 23 of these 29 carcinogens tonnage information is available, the distribution of which shows a clear maximum in the lowest two bands (the annual volume of 12 substances is in the range below 100 t), which could be interpreted to mean that these substances have been considered less relevant by regulatory bodies in the past. The eight carcinogens in the four highest-volume bands of this subgroup (1,000-10,000,000 t/a) are potential regulatory carcinogens. Probably due to this fact of being potential, but not actual regulatory carcinogens they have not been included in past and current programmes for the derivation of OELs for carcinogens at EU or Member State level. For these eight substances the derivation of a BOEL under the CMD or an OEL under the CAD should be considered to be urgent due to their high tonnage.
This observation of the relevance of certain potential regulatory carcinogens emphasises the necessity of permanently scrutinising the ongoing CLH processes for identifying additional substances to be classifi ed as carcinogens (C 1A/1B) at an early stage, in order to decide on the timely derivation of a BOEL under the CMD for them. Because the number of CLH processes covering carcinogenicity has been limited in past years, the future number of additional carcinogens identifi ed in this way for which a BOEL is deemed necessary should be manageable. R-1-Chloro-2,3-epoxypropane 51594-55-9 C 1B, H350 NONS, confi dential Polymer (2-Chloroethyl)(3-epoxypropyl) ammonium chloride 40722-80-3 C 1B, H350 NONS, confi dential Polymer Explanation of notes in Tables 1-3 Column 'Harmonised classifi cation/inclusion in annex I of CMD': IARC: IARC classifi cation; year of publication 
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